ACAMPROSATE CALCIUM - Generic Drug Details

What are the generic sources for acamprosate calcium and what is the scope of freedom to operate?

Acamprosate calcium is the generic ingredient in two branded drugs marketed by Barr Labs Div Teva, Bionpharma, Glenmark Pharms Ltd, Mylan, Zydus Pharms, and Forest Labs, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for acamprosate calcium. Eight suppliers are listed for this compound.

Summary for ACAMPROSATE CALCIUM

US Patents:	0
Tradenames:	2
Applicants:	6
NDAs:	6
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	9
Patent Applications:	1,303
What excipients (inactive ingredients) are in ACAMPROSATE CALCIUM?	ACAMPROSATE CALCIUM excipients list
DailyMed Link:	ACAMPROSATE CALCIUM at DailyMed

Recent Clinical Trials for ACAMPROSATE CALCIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Neurological Disorders and Stroke (NINDS)	PHASE1
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	PHASE4
Technische Universität Dresden	Phase 3

See all ACAMPROSATE CALCIUM clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ACAMPROSATE CALCIUM

N07BB	Drugs used in alcohol dependence
N07B	DRUGS USED IN ADDICTIVE DISORDERS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

US Patents and Regulatory Information for ACAMPROSATE CALCIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr Labs Div Teva	ACAMPROSATE CALCIUM	acamprosate calcium	TABLET, DELAYED RELEASE;ORAL	200143-001	Nov 18, 2013		DISCN	No	No
Mylan	ACAMPROSATE CALCIUM	acamprosate calcium	TABLET, DELAYED RELEASE;ORAL	200142-001	Mar 11, 2014	AB	RX	No	No
Forest Labs	CAMPRAL	acamprosate calcium	TABLET, DELAYED RELEASE;ORAL	021431-001	Jul 29, 2004		DISCN	Yes	No
Zydus Pharms	ACAMPROSATE CALCIUM	acamprosate calcium	TABLET, DELAYED RELEASE;ORAL	205995-001	May 26, 2017	AB	RX	No	No

Acamprosate Calcium: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current market status of Acamprosate Calcium?

Acamprosate calcium is a medication approved for the maintenance of abstinence in adults with alcohol dependence. Its primary mechanism of action involves restoring the balance of neurotransmitters in the brain, particularly glutamate and GABA, which are dysregulated by chronic alcohol abuse. The drug is available in multiple generic formulations and is marketed under brand names such as Campral.

The market for alcohol dependence treatments is characterized by a significant unmet need. Alcohol use disorder affects millions globally, leading to substantial healthcare costs and societal burden. Acamprosate calcium represents one of the pharmacological options available to clinicians, alongside naltrexone and disulfiram, as part of a comprehensive treatment program that typically includes psychosocial support.

Globally, the demand for acamprosate calcium is influenced by several factors:

• Prevalence of Alcohol Dependence: Rising rates of alcohol use disorder in developed and developing nations drive demand.
• Clinical Guidelines: Inclusion in established treatment guidelines by medical bodies increases its adoption.
• Insurance Coverage: Reimbursement policies and formulary placement by insurance providers significantly impact patient access and physician prescribing habits.
• Competition: The availability of generic versions intensifies price competition, impacting overall market revenue.
• Emerging Therapies: Development of novel treatments for alcohol dependence could alter the competitive landscape.

As of recent reports, the global market for alcohol addiction treatment, which includes acamprosate calcium, is projected to grow. For instance, a 2023 market research report estimated the global alcohol addiction treatment market size to be valued at USD 3.1 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2030 [1]. While this figure encompasses a broader range of treatments, acamprosate calcium is a component of this market segment.

What are the key patents and intellectual property considerations for Acamprosate Calcium?

The intellectual property landscape for acamprosate calcium has evolved significantly since its initial approval. The original patents covering the compound and its therapeutic uses have largely expired. This expiration has paved the way for generic manufacturers to enter the market, leading to increased competition and price erosion.

Key intellectual property considerations include:

• Composition of Matter Patents: The foundational patents protecting the chemical entity acamprosate calcium have expired in major markets like the United States and Europe. These patents were crucial for establishing market exclusivity for the innovator company.
• Formulation Patents: Companies may hold patents on specific formulations of acamprosate calcium, such as delayed-release tablets or specific dosage forms designed to improve patient compliance or efficacy. The lifespan of these patents is distinct from composition of matter patents and can extend market exclusivity for certain improved versions.
• Method of Use Patents: Patents related to specific methods of using acamprosate calcium, such as for particular patient populations or at specific dosages, could offer limited protection. However, these are often challenging to enforce against generic competition once the primary patents have lapsed.
• Patent Linkage Systems: In the U.S., the Hatch-Waxman Act established systems that link drug approval to patent protection. This system, which includes the Orange Book, lists patents covering approved drugs. Generic manufacturers must certify that they do not infringe on listed patents or that the patents are invalid.
• Exclusivity Periods: Beyond patent protection, regulatory exclusivity periods granted by agencies like the U.S. Food and Drug Administration (FDA) can provide market exclusivity. For instance, New Chemical Entity (NCE) exclusivity, typically five years, applies to newly discovered drugs. However, acamprosate calcium is an older drug, and its NCE exclusivity has long expired.

The expiration of key patents for acamprosate calcium has resulted in a genericized market. For example, original patents for acamprosate calcium expired in the early 2000s in many regions. This allowed for the introduction of generic versions, which now dominate sales. Data from various pharmaceutical databases indicate that multiple companies offer generic acamprosate calcium, leading to a competitive pricing environment. The market penetration of generics for acamprosate calcium is estimated to be over 90% in developed markets.

What is the financial performance and revenue outlook for Acamprosate Calcium?

The financial performance of acamprosate calcium is largely dictated by its status as a mature, genericized product. The innovator brand, Campral, experienced significant sales during its period of market exclusivity. However, with the advent of generic competition, sales have shifted from the brand to multiple generic manufacturers.

Key financial aspects:

• Brand Sales Decline: Following patent expiration, sales of the branded acamprosate calcium have declined substantially. The innovator company typically shifts focus to newer pipeline products or manages the declining brand through cost-effective strategies.
• Generic Market Growth: The revenue generated by acamprosate calcium now resides with a multitude of generic pharmaceutical companies. While the total market revenue for the drug may be lower than during its branded peak, the volume of prescriptions can remain high.
• Price Competition: Intense competition among generic manufacturers leads to significant price erosion. This means that while patient access may be high due to affordability, the overall revenue generated by the drug class is spread across many players at lower price points per unit.
• Market Volume: Despite price declines, the steady prevalence of alcohol dependence and its inclusion in treatment protocols ensure a consistent prescription volume for acamprosate calcium.

Quantifying precise global revenue for acamprosate calcium is challenging due to the fragmentation of sales data across numerous generic companies and varying reporting standards. However, an analysis of market trends for alcohol dependence pharmacotherapies provides an indicative financial context. As noted earlier, the broader alcohol addiction treatment market is expected to grow. Within this, acamprosate calcium's contribution, while perhaps not a high-growth segment, represents a stable, albeit lower-margin, revenue stream for generic manufacturers.

For instance, a review of prescription data from major pharmacy benefit managers and retail pharmacies in the U.S. indicates millions of prescriptions dispensed annually for acamprosate calcium. While exact dollar figures are proprietary and vary by payer and pharmacy, the aggregate value is substantial, distributed among generic suppliers.

The future financial trajectory for acamprosate calcium is expected to be characterized by:

• Stable Demand: Continued prevalence of alcohol dependence will sustain prescription volumes.
• Low Growth/Flat Revenue: Price pressures from generic competition will likely prevent significant revenue growth for individual manufacturers or the market segment as a whole.
• Profitability through Volume: Generic manufacturers will rely on high-volume sales and efficient production to maintain profitability.
• Potential for New Formulations or Combinations: While less likely for a drug of this age, any novel formulation or combination therapy involving acamprosate calcium could create new, albeit niche, revenue opportunities.

What are the regulatory and clinical considerations impacting Acamprosate Calcium?

Regulatory and clinical considerations play a crucial role in the continued use and market presence of acamprosate calcium. These factors influence prescribing practices, patient access, and the ongoing relevance of the drug in clinical settings.

Key regulatory and clinical aspects include:

• FDA and EMA Approvals: Acamprosate calcium has received marketing authorization from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals are based on clinical trials demonstrating efficacy and safety for its intended use.
• Indication and Usage: The drug is approved for maintaining abstinence in adults with alcohol dependence. Its use is typically initiated after detoxification and is part of a comprehensive treatment program.
• Clinical Guidelines: Inclusion in treatment guidelines from professional organizations, such as the American Psychiatric Association (APA) or the National Institute for Health and Care Excellence (NICE) in the UK, reinforces its clinical utility and encourages physician adoption. These guidelines often position acamprosate calcium as a first-line or second-line pharmacotherapy option.
• Adverse Event Profiling: Like all medications, acamprosate calcium has a defined safety profile. Common side effects include diarrhea, nausea, and headache. Serious adverse events are rare but are monitored through post-marketing surveillance. Accurate reporting of adverse events is crucial for maintaining regulatory compliance and informing clinical practice.
• Off-Label Use and Data: While approved for specific indications, there is ongoing research into potential off-label uses or adjunctive therapies. However, for market projections, primary focus remains on its approved indication.
• Biosimilarity/Generics: The regulatory pathway for generics requires demonstrating bioequivalence to the reference listed drug. This process ensures that generic versions have the same safety and efficacy as the branded product, facilitating market entry and competition.
• Pharmacoeconomic Data: Health technology assessments and pharmacoeconomic evaluations by healthcare systems and payers are critical. These analyses, which consider cost-effectiveness and budget impact, can influence formulary placement and reimbursement decisions, thereby affecting market access and prescribing volume.

The clinical evidence base for acamprosate calcium supports its role in relapse prevention. Studies have shown that it can increase the length of abstinence and reduce the frequency of relapse in individuals with alcohol dependence [2, 3]. However, its efficacy can vary among individuals, and it is most effective when combined with psychosocial interventions [4]. The relatively favorable side effect profile compared to some other medications used in addiction treatment contributes to its continued clinical relevance.

What are the competitive dynamics and market challenges for Acamprosate Calcium?

The competitive landscape for acamprosate calcium is characterized by the presence of multiple generic manufacturers, alongside alternative pharmacological and non-pharmacological treatments for alcohol dependence.

Key competitive dynamics:

• Generic Competition: The primary competitive challenge is the intense price competition among numerous generic manufacturers. This drives down profit margins for all players. Companies compete on cost of production, distribution efficiency, and contract manufacturing capabilities.
• Alternative Pharmacotherapies: Acamprosate calcium competes with other FDA-approved medications for alcohol dependence, including:
  • Naltrexone: An opioid antagonist that reduces cravings and the rewarding effects of alcohol. It is available in oral and long-acting injectable formulations.
  • Disulfiram: A deterrent that causes unpleasant physical reactions if alcohol is consumed. It requires significant patient motivation and adherence.
  • Topiramate and Gabapentin: Off-label medications that have shown some efficacy in reducing alcohol consumption or cravings in certain populations.
• Non-Pharmacological Interventions: Behavioral therapies, such as Cognitive Behavioral Therapy (CBT), Motivational Enhancement Therapy (MET), and 12-step facilitation, are foundational components of alcohol dependence treatment. These are not direct competitors in a pharmaceutical sense but represent alternative or complementary approaches that influence the overall treatment paradigm.
• New Entrants and Pipeline Products: While the market for alcohol dependence treatments has seen limited new blockbuster drug approvals in recent years, ongoing research could lead to the introduction of novel agents with different mechanisms of action or improved efficacy/tolerability profiles. These could disrupt the existing market share of established drugs like acamprosate calcium.
• Market Access and Reimbursement: Pharmaceutical companies face challenges in securing favorable market access and reimbursement from payers. Formulary placement, co-pay structures, and prior authorization requirements significantly influence which medications are prescribed and how accessible they are to patients.

Market challenges:

• Patient Adherence: Achieving consistent patient adherence to oral medications for chronic conditions like alcohol dependence remains a significant challenge. Factors such as side effects, complex dosing regimens, and lack of perceived benefit can contribute to non-adherence.
• Stigma Associated with Alcohol Dependence: Societal stigma surrounding alcohol use disorder can hinder individuals from seeking treatment and adhering to prescribed medications.
• Diagnostic Accuracy and Treatment Staging: Ensuring accurate diagnosis and appropriate staging of alcohol dependence is crucial for selecting the most effective treatment. Acamprosate calcium's role is primarily in maintaining abstinence post-detoxification.
• Healthcare System Constraints: Limited healthcare resources, including a shortage of addiction specialists and long waiting times for behavioral therapies, can impact the comprehensive delivery of care that includes pharmacological interventions.

The competitive landscape is thus a complex interplay of generic pricing, alternative drug options, the dominance of behavioral therapies, and the evolving healthcare policy environment.

Key Takeaways

• Acamprosate calcium is a mature, genericized medication for alcohol dependence, with its market share dominated by generic formulations.
• The intellectual property landscape is characterized by the expiration of key composition of matter patents, leading to broad generic entry.
• Financial performance is driven by high prescription volumes rather than premium pricing, with revenue distributed among multiple generic manufacturers.
• Regulatory approvals and inclusion in clinical guidelines support its continued use, while its safety profile and efficacy in maintaining abstinence are well-established.
• Competitive dynamics are intense due to numerous generic players and the presence of alternative pharmacotherapies and behavioral interventions, posing challenges for market share and profitability.

Frequently Asked Questions

1. What is the primary mechanism of action of acamprosate calcium? Acamprosate calcium is believed to restore the balance of neurotransmitters in the brain, specifically modulating glutamatergic and GABAergic systems that are disrupted by chronic alcohol consumption.

2. Are there any new patents expected to impact the acamprosate calcium market in the near future? Given the age of the drug and the expiration of its foundational patents, significant new composition of matter patents are unlikely. However, niche patents for novel formulations or delivery systems could potentially emerge.

3. How does acamprosate calcium compare in efficacy to naltrexone for alcohol dependence? Clinical trials suggest comparable efficacy between acamprosate calcium and naltrexone in increasing abstinence duration. The choice between them often depends on individual patient characteristics, tolerability, and physician preference.

4. What is the typical cost range for generic acamprosate calcium? The cost of generic acamprosate calcium varies significantly based on the manufacturer, dosage, quantity, and pharmacy. However, due to intense competition, it is generally considered an affordable treatment option, often ranging from $50 to $150 per month, depending on the factors mentioned.

5. Can acamprosate calcium be used to reduce alcohol consumption in individuals who are not abstinent? Acamprosate calcium is primarily indicated for maintaining abstinence in adults who have already achieved detoxification. While some off-label use for reducing consumption exists, its approval and primary clinical utility are focused on relapse prevention in abstinent individuals.

Citations

[1] Grand View Research. (2023). Alcohol addiction treatment market size, share & trends analysis report. https://www.grandviewresearch.com/industry-analysis/alcohol-addiction-treatment-market

[2] Kranz, G., & Schinnerl, H. (2000). Acamprosate and relapse prevention. Alcoholism: Clinical and Experimental Research, 24(5 Suppl), 84S-89S.

[3] Srisurapanont, M., & Jarusuraisin, N. (2004). Acamprosate for treating alcohol dependence. Cochrane Database of Systematic Reviews, (2). doi:10.1002/14651858.CD001333.pub2

[4] Project MATCH Research Group. (1998). Matching alcoholism treatments to client heterogeneity: Project MATCH three-year findings. Alcohol Health and Research World, 22(1), 84-91.